Top Story

Fibroblast growth factor 23 linked to rare diseases, CKD

May 19, 2015

NASHVILLE, Tenn. — Hypophosphatemic rickets, tumor-induced osteomalacia and chronic kidney disease may at first appear different from one another, yet they share a common thread — fibroblast growth factor 23, known as FGF23, plays an important role in all three.

According to a presenter at the 24th annual American Association of Clinical Endocrinologists Scientific & Clinical Congress, FGF23, a circulating endocrine hormone of the fibroblast growth factor family first discovered in 2000, promotes phosphate waste in the kidneys, affects the body’s ability to synthesize vitamin D and may even be a novel cardiovascular risk factor.

Rifka Schulman Meeting News Coverage

Pamidronate preserves renal function, improves mortality in chronic critical illness

May 16, 2015
NASHVILLE, Tenn. — Use of the intravenous bisphosphonate pamidronate to prevent bone resorption was associated with improved mortality, ventilator discontinuation…
Merril Mageli Meeting News Coverage

CV biomarkers unchanged following oral testosterone therapy

May 15, 2015
NASHVILLE, Tenn. — Daily oral testosterone did not significantly increase biomarkers of cardiovascular risk in hypogonadal men, compared with transdermal…

Risks, rewards increase for older transgender adults

May 1, 2015
When Olympic gold medalist and reality star Bruce Jenner came out as transgender in a high-profile television interview, a national audience was able to put a well-known…
More News Headlines »
In the Journals

Average vocal pitch decrease linked to testosterone dosing

April 17, 2015
Dose- and concentration-dependent decrease in average vocal pitch was found among women with higher levels of…
More »
Meeting News Coverage Video
4131397887001 th

Vlog: Global endocrinology community gathers for ICE/ENDO 2014

June 21, 2014
Ronald Tamler, MD, PhD, MBA, clinical director of the Mount Sinai Diabetes Center and a member of the Endocrine Today
More »
Current Issues
View the Current Issues